Author

Ryota Hashimoto

National Center of Neurology and Psychiatry - Cited by 23,217 - psychiatry

Biography

Myself Ryota Hashimoto. I am from Japan. I am Department of Physiology, Juntendo University Faculty of Medicine, Tokyo. My area of interests are Induced Smooth muscle cells; Bone marrow-derived; Vascular grafts; Arterial pressure; Contractility; Ion channels; Tissue engineering
Title
Cited by
Year
Toward recovery in schizophrenia: Current concepts, findings, and future research directions
T Onitsuka, Y Hirano, T Nakazawa, K Ichihashi, K Miura, K Inada, ...Psychiatry and clinical neurosciences 76 (7), 282-291, 202
22
2022
Cross-disorder analysis of genic and regulatory copy number variations in bipolar disorder, schizophrenia, and autism spectrum disorder
I Kushima, M Nakatochi, B Aleksic, T Okada, H Kimura, H Kato, ...Biological Psychiatry 92 (5), 362-374, 2022202
18
2022
Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: a multi-atlas segmentation study
T Takahashi, S Tsugawa, S Nakajima, E Plitman, MM Chakravarty, ...Schizophrenia Research 243, 268-275, 2022202
13
2022
Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese Society of mood disorders
H Baba, S Kito, K Nukariya, M Takeshima, N Fujise, J Iga, H Oshibuchi, ...Psychiatry and Clinical Neurosciences 76 (6), 222-234, 2022202
11
2022
A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive …
H Yamada, M Motoyama, N Hasegawa, K Miura, J Matsumoto, K Ohi, ...BJPsych Open (3), e3, 2022202
8
2022
Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry
K Ogasawara, S Numata, N Hasegawa, M Nakataki, M Makinodan, K Ohi, ...Neuropsychopharmacology Reports 42 (2), 221-225, 2022202
8
2022
Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: a real-world …
S Ochi, H Tagata, N Hasegawa, N Yasui-Furukori, J Iga, H Kashiwagi, ...International Journal of Neuropsychopharmacology 25 (10), 818-826, 2022202
7
2022
Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA. 1, BA. 2, and BA. 5
T Tamura, D Yamasoba, Y Oda, J Ito, T Kamasaki, N Nao, R Hashimoto, ...Communications Biology (1), 772, 2023202
6
2023
Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium
D Schijven, MC Postema, M Fukunaga, J Matsumoto, K Miura, ...Proceedings of the National Academy of Sciences 120 (14), e2213880120, 2023202
6
2023
Genetics of autism spectrum disorders and future direction
Y Yasuda, J Matsumoto, K Miura, N Hasegawa, R HashimotoJournal of Human Genetics 8 (3), 193-197, 2023202
6
2023
Sex differences in social cognition and association of social cognition and neurocognition in early course schizophrenia
R Kubota, R Okubo, S Ikezawa, M Matsui, L Adachi, A Wada, C Fujimaki, ...Frontiers in Psychology 13, 867468, 2022202
5
2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study
H Muraoka, F Kodaka, N Hasegawa, N Yasui-Furukori, K Fukumoto, ...Asian Journal of Psychiatry 74, 103174, 2022202
5
2022
Cognitive performances across individuals at high genetic risk for schizophrenia, high genetic risk for bipolar disorder, and low genetic risks: a combined polygenic risk score …
K Ohi, D Nishizawa, S Sugiyama, K Takai, D Fujikane, A Kuramitsu, ...Psychological Medicine, 1-10, 2022202
3
2022
Treatment‐resistant schizophrenia in patients with 3q29 deletion: A case series of four patients
Treatment‐resistant schizophrenia in patients with q29 deletion: A case series of four patientsY Nawa, I Kushima, B Aleksic, M Yamamoto, H Kimura, M Banno, ...Psychiatry and Clinical Neurosciences 76 (7), 8-9, 2022202
3
2022
Oxidative stress‐induced phosphorylation of JIP4 regulates lysosomal positioning in coordination with TRPML1 and ALG2
Y Sasazawa, S Souma, N Furuya, Y Miura, S Kazuno, S Kakuta, A Suzuki, ...The EMBO Journal 41 (22), e111476, 2022202
3
2022
Prescription of anticholinergic drugs in patients with schizophrenia: analysis of antipsychotic prescription patterns and hospital characteristics
H Hori, N Yasui-Furukori, N Hasegawa, J Iga, S Ochi, K Ichihashi, ...Frontiers in Psychiatry 1, 82826, 2022202
3
2022
X chromosome aneuploidies and schizophrenia: association analysis and phenotypic characterization
I Kushima, B Aleksic, H Kimura, M Nakatochi, T Lo, M Ikeda, M Arai, ...Psychiatry and clinical neurosciences 76 (1), 667-673, 0
2
2022
The effect of ketamine on eye movement characteristics during free-viewing of natural images in common marmosets
Z Polyakova, M Iwase, R Hashimoto, M YoshidaFrontiers in neuroscience 6, 02300, 2022202
1
2022
Oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome
T Takemoto, M Baba, K Yokoyama, K Kitagawa, K Nagayasu, Y Ago, ...Molecular brain 5 (), -5, 2022202
1
2022
Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”
K Inada, K Fukumoto, N Hasegawa, Y Yasuda, H Yamada, H Hori, ...Neuropsychopharmacology Reports 42 (4), 502-509, 2022202
1
2022

Referred From: https://scholar.google.co.jp/citations?user=8tfXKQkAAAAJ&hl=en

Cited by
Citations 23217
h-index 75
i10-index 297
Recommended Journals
Open Access Journals